Product
Telaglenestat
1 clinical trial
4 indications
Indication
Solid TumorsIndication
NSCLCIndication
Colorectal cancerIndication
KRAS Gene MutationClinical trial
A Phase 1b/2, Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination With CDK4/6 Inhibitor Palbociclib in Patients With Advanced or Metastatic Solid TumorsStatus: Completed, Estimated PCD: 2021-09-24